A phase I study of interleukin-2 in children with cancer.
about
Immune-based therapeutics for pediatric cancer.Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool.NK cell-based immunotherapies in Pediatric Oncology.Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow.
P2860
A phase I study of interleukin-2 in children with cancer.
description
1992 nî lūn-bûn
@nan
1992 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
A phase I study of interleukin-2 in children with cancer.
@ast
A phase I study of interleukin-2 in children with cancer.
@en
type
label
A phase I study of interleukin-2 in children with cancer.
@ast
A phase I study of interleukin-2 in children with cancer.
@en
prefLabel
A phase I study of interleukin-2 in children with cancer.
@ast
A phase I study of interleukin-2 in children with cancer.
@en
P2093
P1476
A phase I study of interleukin-2 in children with cancer.
@en
P2093
Colamonici OR
Gillespie A
Hammond GD
Neckers LM
P304
P577
1992-11-01T00:00:00Z